Transition Bio is a microfluidics-driven drug discovery platform company working to establish a one-of-a-kind technology platform to revolutionize condensate drug discovery. With a physics-first approach that enables proprietary data generation that in turn maps condensate behavior on an unprecedented scale, we aim to be the leading technology and data-driven company in the new and rapidly expanding field of condensate cell biology. Our founders and world-class team integrate the latest advances in the fields of physics, chemistry, biology and machine learning to harness the potential of biomolecular condensates to solve some of today's most fundamental challenges in health and disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/10/23 | $50,000,000 | Series A |
Bristol Myers Squibb LifeForce Capital Magnetic Ventures Northpond Ventures  Taiho Ventures | undisclosed |
